This update bulletin presents key opinion leader (KOL) insights on recent events in the ovarian cancer treatment landscape. Topics covered include; the US approval and launch of Tesaro's PARP inhibitor Zejula (niraparib) for the maintenance treatment of recurrent ovarian cancer that is in complete or partial response to platinum-based chemotherapy; the Phase III ARIEL3 trial of Clovis’ PARP inhibitor Rubraca (rucaparib) meeting its primary endpoint of improved progression-free survival (PFS) in platinum-sensitive, high-grade ovarian, fallopian tube, or primary peritoneal cancer; and the new data from the Phase I/II ECHO-204 trial evaluating Incyte’s IDO1 inhibitor epacadostat plus Bristol-Myers Squibb’s PD-1 inhibitor Opdivo (nivolumab) in multiple solid tumours types, including ovarian cancer, presented at ASCO 2017.
How do KOLs view the US approval of Tesaro's Zejula?
How will Zejula be used in the treatment of ovarian cancer?
How will oncologists choose between the PARP inhibitors, and how is their comparative efficacy viewed, in the platinum-sensitive, maintenance setting?
How do the KOLs interpret the results of the ARIEL3 trial of Clovis’ Rubraca, and how do they view the overall significance of these data?
Where do KOLs see Rubraca fitting into the ovarian cancer treatment algorithm in the longer term?
How do KOLs view the findings from the ECHO-204 trial of Bristol-Myers Squibb’s PD-1 inhibitor Opdivo in combination with Incyte’s IDO1 inhibitor epacadostat?
How do KOLs view the overall potential for combining an IDO inhibitor with a PD-1 inhibitor in the treatment of ovarian cancer and what could increase the chance of success for such combinations?